DLBCL

Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.

Two immune systems conditions, hypogammaglobulinemia and hypocomplementemia, may be predictive of adverse outcomes in patients with diffuse large B-cell lymphoma, according to a published study.

Patients with relapsed or refractory diffuse large B-cell lymphoma who have not found success in 2 or more lines of therapy face stiff odds, but new data suggest polatuzumab vedotin–based therapies may help improve outcomes.

The first CD19/22-directed dual targeting CAR T cell AUTO3 demonstrated a tolerable and best-in-class safety profile as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S. Nowakowski, MD, discusses the remaining unmet needs that exist in the treatment landscape of diffuse large B-cell lymphoma.

Despite concerns about treatment-related immunosuppression, a report out of Spain suggests SARS-CoV-2 precautions can offset risk for patients with diffuse large B-cell lymphoma.

A review was conducted to understand how precision medicine strategies can be successfully implemented in diffuse large B-cell lymphoma